Project Summary
The goal of this program is to initiate commercialization of a mass spectrometry (MS)-based workflow for
the diagnosis and classification of membranous nephropathy (MN), a leading cause of nephrotic syndrome,
leading to kidney failure in a third of patients. Since the 1950’s, most forms of MN were considered idiopathic in
origin, however, based on numerous publications in recent years, it is now broadly accepted that MN is caused
by autoantibodies against approximately 20 different endogenous human proteins. The most common MN
autoantigen is the phospholipase A2 receptor (PLA2R), and serological analysis of autoantibody titers against
this protein has proven to be an indispensable serological tool for monitoring disease progression, severity, and
remission (1-3). Arkana and others have identified additional novel autoantigens in MN cases (4-9), and given
the success of PLA2R serological testing for personalized treatment, the characterization and clinical validation
of the remaining MN autoantigens is urgently required. Furthermore, follow-up investigation of patients positive
for these newly identified autoantigens have been linked to life-threatening comorbidities including cancer and
specific autoimmune diseases. Because classifying patients based on MN autoantigen may reveal severe
underlying conditions, and PLA2R serology will identify only 70% of primary cases, Arkana has partnered with
proteomics experts at the University of Arkansas for Medical Sciences (UAMS) to develop an unbiased, MS-
based approach to classifying MN of all antigen types. Phase I studies evaluated nearly 300 tissue biopsies from
MN patients with previously determined autoantigens including PLA2R, thrombospondin type-1 domain
containing 7A (THSD7A) (10), and exostosin1/2 (EXT1/2) (11), with triple negative cases also included. After
evaluating a range of computational, statistical, and artificial intelligence data analysis modalities, ranked Z-
scores were found to be an effective metric for autoantigen classification, correctly classifying over 95% of
samples. During the proposed Phase II program, Arkana will continue collaborating with UAMS to translate this
powerful method to clinical practice and commercial availability. Quality control metrics will be developed for the
inclusion/exclusion of incoming samples, to ensure the reliability and repeatability of MS analysis and support
verification of autoantigen classifications. The analytical pipeline will also be broadened to accommodate
additional autoantigen targets, many of which were identified by Arkana’s recent MS analysis of hundreds of
biobanked MN samples. Finally, the method will be transferred to Arkana’s CLIA laboratory and validated in a
comparative study with UAMS comprising approximately 300 blinded samples representing the full breadth of
MN autoantigen classes. Launching this workflow as a commercially available service will not only offer clinicians
unprecedented detail for the diagnosis and treatment of MN patients, but also reveal potentially life-threatening
comorbidities undetectable by prior generation strategies.
